Preclinical Development of a vaccine for HTLV-1

Project summary

Human T-lymphotropic virus type-1 (HTLV-1) is a cause of T-cell leukemia/lymphoma as well as severe autoimmune disorders. An estimated 5-10 million individuals are infected globally, with Indigenous populations in central Australia most highly affected. Using the second-generation molecular Clamp platform, we seek to develop a candidate HTLV-1 glycoprotein vaccine using the Molecular Clamp and utilise this antigen to discover neutralising monoclonal antibodies as potential therapeutic agents.

Patents

Improved chimeric polypeptides and uses thereof https://patents.google.com/patent/AU2023242948A1/en

Key publications

Journal Article

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

Tardiota, Nicolas, Jaberolansar, Noushin, Lackenby, Julia A., Chappell, Keith J. and O’Donnell, Jake S. (2024). HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors. Virology Journal, 21 (1) 14, 14. doi: 10.1186/s12985-024-02288-z

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors

2024

Journal Article

Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease

O’Donnell, Jake S., Jaberolansar, Noushin and Chappell, Keith J. (2024). Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease. The Lancet Microbe, 5 (4), e400-e408. doi: 10.1016/s2666-5247(23)00359-2